CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 249 target
Drug / intervention
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05673057
NCT05673057Phase 2ActiveMonitorCompletion was 1mo ago
Slow Enrollment
CompareCT.gov

A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Molecular Partners AG·interventional·Posted Jan 6, 2023·Updated Jun 9, 2026

In Brief

A Phase 2 clinical trial evaluating MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, and 4 other interventions for Leukemia and 3 related conditions. Active but no longer recruiting, targeting 249 participants across 9 sites in 4 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute, Newly Diagnosed
CountriesFrance, Lithuania, Netherlands, Switzerland
Collaborators--

Timeline

Phase 2Active
20232024202520262027
First PostedJan 6, 2023
Enrollment StartDec 29, 2022
Primary CompletionMay 29, 2026
Study CompletionMay 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 3.5 years ago

Interventions

MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1drug

MP0533 is administered by intravenous infusion

MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm Adrug

* MP0533 is administered by intravenous infusion * Obinutuzumab pretreatment administered

MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclaxdrug

* MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered

MP0533 with Obinutuzumab pretreatmentdrug

* MP0533 is administered by intravenous infusion at densified dosing schedule * Obinutuzumab pretreatment administered

MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AMLdrug

* MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered

MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patientsdrug

* MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered